Abstract

A transcription overriding cassette (TORC) composed for the expression of at least one gene of interest, characterised in that the TORC comprises two parts, one being a first DNA sequence comprising a strong constitutive promoter DNA sequence having at least 50% nucleotide identity with the promoter DNA sequence according to SEQ ID 6 and one being a second DNA sequence having at least 50% nucleotide identity with SEQ ID 23. The first DNA sequence is located directly before the second DNA sequence within the TORC and the first and second DNA sequences are connected directly to each other within the complete sequence of the TORC or are separated from each other within the complete sequence of the TORC by DNA sequences of DNA restriction cleavage sites.

IPC Classes  ?

• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Abstract

The present invention refers to a diagnostic method for the ex-vivo prognosis, prediction or risk stratification for mortality, disease outcome or ICU admission of a patient who has been diagnosed with community acquired pneumonia (CAP) comprising the steps of i) providing a sample that has been obtained from the patient and ii) analysing the expression level of at least one nucleic acid in the sample, wherein the patient's prognosis, prediction or risk stratification is determined according to the expression levels of the at least one nucleic acid. The at least on nucleic acid is selected from a gene signature comprising biomarkers as identified in the present invention. In further aspects the present invention also refers to the nucleic acids of the gene signature and their use for prognosis and risk stratification. Finally, the present invention also refers to a diagnostic kit for performing the method of the invention.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

Provided herein are methods for treating pulmonary hypertension. The methods include formulation of stable and highly concentrated imatinib solutions, selection of inhalers and nebulizers capable of aerosolizing such stable and highly concentrated imatinib solutions and administering to a subject an effective dose of imatinib, wherein imatinib solution is aerosolized using a nebulizer and inhaled by the subject. In preferred embodiments, the nebulizer is selected from the group of soft mist inhalers, such as the Medspray™ wet aerosol inhaler or the Respimat™. Provided herein are methods for treating pulmonary hypertension. The methods include formulation of stable and highly concentrated imatinib solutions, selection of inhalers and nebulizers capable of aerosolizing such stable and highly concentrated imatinib solutions and administering to a subject an effective dose of imatinib, wherein imatinib solution is aerosolized using a nebulizer and inhaled by the subject. In preferred embodiments, the nebulizer is selected from the group of soft mist inhalers, such as the Medspray™ wet aerosol inhaler or the Respimat™. A method of treating a patient suffering from pulmonary hypertension, comprising: (a) providing stable and highly concentrated imatinib solutions (b) providing an aerosol producing device capable of aerosolizing such stable and highly concentrated imatinib solutions (b) administering to the patient an effective dose of imatinib by inhalation.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers

Abstract

The invention relates to a method for determining a score value (S) for the likelihood of the presence of a pulmonary hypertension (PH) in a person (P).

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

Provided are diamondoid salts, electrolytes comprising the diamondoid salts, and electrochemical devices incorporating the diamondoid salts or electrolytes. In embodiments, an electrolyte for an electrochemical device comprises a metallic salt and a diamondoid salt, the diamondoid salt comprising a diamondoid-functionalized cationic core and a counter anion, the diamondoid-functionalized cationic core comprising a cationic core and a diamondoid group covalently bound to the cationic core.

IPC Classes  ?

• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• C25B 3/26 - Reduction of carbon dioxide
• H01M 10/0567 - Liquid materials characterised by the additives
• H01M 10/0568 - Liquid materials characterised by the solutes

Abstract

The invention relates to a cleaning device (1) for removal of biofilms in a dental region (2). The cleaning device comprises a connection (10) for supply of fluid and of electrical energy, a shaft (20) through which fluid is able to flow, and, arranged within the shaft, first and second electrical lines (40, 50) having first and second electrodes (410, 510), respectively. The cleaning device further comprises a tip (60), wherein the tip is designed to be connectable to the second electrical line (50) such that it can serve as second electrode (510). Current is able to flow in the region arranged between the first electrode and the second electrode and irrigated by fluid, such that reactive compounds and/or gases can form in the fluid, which remove biofilms from the dental region (2) that is to be cleaned.

IPC Classes  ?

• A61C 17/02 - Rinsing or air-blowing devices, e.g. using fluid jets
• A61L 2/03 - Electric current, e.g. electrolysis
• A61C 17/20 - Power-driven cleaning or polishing devices using ultrasonics

Abstract

The invention relates to an attachment (100) for cleaning and removing a biofilm from implants, comprising at least: • a connector (1) for connecting to a base unit (200) for providing fluid and electrical energy, having an adapter (1a) for introducing fluid in order to supply the attachment (100) with fluid from the base unit (200), and an adapter (1b) for introducing electrical energy from the base unit (200) into the attachment (100); • a rod (2) through which a fluid can flow, having at least one first opening (2a) in the direction of the implant (500) to be cleaned and a second opening (2b) for connecting the rod (2) to the adapter (1a) of the connector (1), wherein there is a cavity (2c) between the at least one first opening (2a) and the second opening (2b), through which a fluid can freely flow, wherein the rod (2) through which a fluid can flow can be connected to the connector (1) such that a fluid can flow through the adapter (1a) via the second opening (2b) and the cavity (2c) through the at least one first opening (2a); • wherein the rod (2) comprises an integrated first electrical conductor (3) with an exposed cathode (3a), which can be connected to the negative pole of the adapter (1b) of the connector (1) in such a way that current can flow between the base unit (200) and an implant (500) via the attachment (100). The attachment (100) further comprises a second electrical conductor (4) with an anode (4a), which can be connected to the positive pole of the adapter (1b) of the connector (1) in such a way that current can flow via an implant from the first electrical conductor to the electrical conductor (4).

IPC Classes  ?

• A61L 2/00 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lensesAccessories therefor
• A61L 2/03 - Electric current, e.g. electrolysis
• A61C 17/00 - Devices for cleaning, polishing, rinsing or drying teeth, teeth cavities or prosthesesSaliva removersDental appliances for receiving spittle

Abstract

The mixture of substances according to the invention for producing a composite material comprises the following components: water, gelling agent with a mass fraction of 0.01% to 6%, algae with a mass fraction of 0.01% to 0.8%, cyanobacteria with a mass fraction of 0.01% to 0.8% and chitin with a mass fraction of 0.05% to 3.0%. The composite material produced from this mixture of substances can be processed into any shapes and can be used for example to produce printed circuit boards, packaging material, paper or as a gel-like dressing material or applicator for drugs on skin surfaces.

IPC Classes  ?

• C08L 5/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• C08J 5/18 - Manufacture of films or sheets
• C08L 5/12 - Agar-agarDerivatives thereof
• C08L 89/00 - Compositions of proteinsCompositions of derivatives thereof

Abstract

1+x1-x2232323122-alcohol mixture or a water/acetone mixture.

IPC Classes  ?

• H01M 4/04 - Processes of manufacture in general
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 4/02 - Electrodes composed of, or comprising, active material
• C01G 53/00 - Compounds of nickel
• H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
• H01M 4/1391 - Processes of manufacture of electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx

Abstract

1−x−y-zyz22, and the surfaces of the core particles exhibit a coating comprising at least one polycationic organic polymer or at least one polyanionic organic polymer.

IPC Classes  ?

• H01M 4/04 - Processes of manufacture in general
• H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
• H01M 4/1391 - Processes of manufacture of electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
• H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 10/0562 - Solid materials
• H01M 10/0565 - Polymeric materials, e.g. gel-type or solid-type
• H01M 10/0568 - Liquid materials characterised by the solutes
• H01M 10/0569 - Liquid materials characterised by the solvents

Abstract

A beverage comprising at least one fermentative extract, characterized in that the fermentative extract is obtained from at least one agricultural secondary flow, the at least one agricultural secondary flow being an agricultural secondary flow from the production of spices, for example a saffron secondary flow that comprises entire flowers and/or petals and/or anthers and/or stigmata of the saffron plant.

IPC Classes  ?

• A23F 3/40 - Tea flavourTea oilFlavouring of tea or tea extract
• A23L 27/24 - Synthetic spices, flavouring agents or condiments prepared by fermentation
• C12C 5/02 - Additives for beer
• A23F 3/10 - Fermentation with addition of microorganisms or enzymes
• A23L 2/38 - Other non-alcoholic beverages
• C12G 1/022 - FermentationMicrobiological or enzymatic treatment
• C12G 3/02 - Preparation of other alcoholic beverages by fermentation
• A23L 2/52 - Adding ingredients
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives

Abstract

Described are a coated particulate material for use in an electrode of an electrochemical cell and a process for preparing said coated particulate material, an electrode comprising said coated particulate material, an electrochemical cell comprising said coated particulate material, and a use of said coated particulate material for preparing an electrode for use in an electrochemical cell.

IPC Classes  ?

• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
• H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 10/0569 - Liquid materials characterised by the solvents
• H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
• H01M 10/48 - Accumulators combined with arrangements for measuring, testing or indicating the condition of cells, e.g. the level or density of the electrolyte

Abstract

The invention is concerning a medical preparation comprising bicyclic heptapeptides for use in vertebrates or humans suffering from an infection caused by Gram-negative bacteria like Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, Neisseria gonorrhoeae, Chlamydia trachomatis, Shigella sonnei, Salmonella enterica Typhimurium LT2, Enterobacter spp., Bifidobacterium longum, Bacteroides fragilis, Lactobacillus reuteri, Enterococcus spp., Yersinia pestis and numerous other Gram-negative bacteria.

IPC Classes  ?

• C07K 7/64 - Cyclic peptides containing only normal peptide links
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Abstract

30322433 and CAS number 2222941-37-7. Synonyms are CCS1477, inobrodib, inobrodibum, CCS-1477, CCS 1477, CBP-IN-1 or CBP/p300-IN-4.

IPC Classes  ?

• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 9/12 - Antihypertensives
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

283343 3 and the CAS registry number 1613695-14-9. The synonyms are SGC-CBP30, SGCCBP30, or SGC CBP30

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

Provided herein are methods for treating pulmonary hypertension. The methods include formulation of stable and highly concentrated imatinib solutions, selection of inhalers and nebulizers capable of aerosolizing such stable and highly concentrated imatinib solutions and administering to a subject an effective dose of imatinib, wherein imatinib solution is aerosolized using a nebulizer and inhaled by the subject. In preferred embodiments, the nebulizer is selected from the group of soft mist inhalers, such as the Medspray™ wet aerosol inhaler or the Respimat™. A method of treating a patient suffering from pulmonary hypertension, comprising: (a) providing stable and highly concentrated imatinib solutions (b) providing an aerosol producing device capable of aerosolizing such stable and highly concentrated imatinib solutions (b) administering to the patient an effective dose of imatinib by inhalation.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/12 - AerosolsFoams
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 9/08 - Vasodilators for multiple indications

Abstract

xyzyy) (z < x). The second gas is transported to a sulphur precipitation chamber in which sulphur is precipitated. The process makes it possible to obtain pure tellurium from CdTe in an energy-saving, cost-saving and faster way. The invention also relates to a plant suitable for carrying out the process according to the invention.

IPC Classes  ?

• C01B 19/02 - Elemental selenium or tellurium

Abstract

Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject an effective amount of iloprost on demand or as rescue medication (also referred to as pro re nata, PRN), wherein iloprost is administered to the subject via inhalation using a portable soft mist inhaler. In preferred embodiments, the soft mist inhaler is the RespimatTMor the MedsprayTM wet aerosol inhaler. A method of treating a patient suffering from pulmonary hypertension, comprising: (a) providing a portable and pre-filled soft mist inhaler adapted for delivering an effective amount of iloprost; and (b) administering to the patient the effective amount of iloprost by inhalation on an as-needed basis.

IPC Classes  ?

• A61K 31/5578 - Eicosanoids, e.g. leukotrienes having a pentalene ring system, e.g. carbacyclin, iloprost
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 9/08 - Vasodilators for multiple indications
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention provides a new system, resp. method, of genetic modification, called ACIT (Alphaproteobacteria chromosomally inserting transcription-control cassette). The invention, however, is not limited to use in Alphaproteobacteria. The modification can be implemented within the bacterial chromosome and therefore permanently implemented within the microorganism.

IPC Classes  ?

• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
• C12N 15/72 - Expression systems using regulatory sequences derived from the lac-operon
• C12N 15/67 - General methods for enhancing the expression

Abstract

NNNN'-phenyl-piperazine, a silent agonist of the mammalian α7 nicotinic acetylcholine receptor, are provided. These silent agonists control the desensitization state of the receptor. Further provided are pharmaceutical compositions that allow the administration of the silent agonists of the disclosure to a subject animal or human in need of treatment for a pathological condition arising from such as inflammation. The novel silent agonists also may be co-administered to a patient simultaneously or consecutively with a type II positive allosteric modulator to modulate the activity of the receptor.

IPC Classes  ?

• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/452 - Piperidinium derivatives
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• C07D 211/56 - Nitrogen atoms
• C07D 211/58 - Nitrogen atoms attached in position 4

Abstract

The invention is about a device, for example a microsphere, constructed for the slow release of pharmaceutically or microbiologically active substances and its use for disinfection of wounds/niches/periodontal pockets.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/50 - Microcapsules
• A61K 9/06 - OintmentsBases therefor
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 31/05 - Phenols
• A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/4425 - Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
• A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
• A61K 33/18 - IodineCompounds thereof
• A61K 33/20 - Elemental chlorineInorganic compounds releasing chlorine
• A61K 33/32 - ManganeseCompounds thereof
• A61K 33/38 - SilverCompounds thereof
• A61K 33/40 - Peroxides
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• A61P 11/02 - Nasal agents, e.g. decongestants
• A61P 11/04 - Drugs for disorders of the respiratory system for throat disorders
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/02 - Local antiseptics
• A61P 31/04 - Antibacterial agents

Abstract

The subject matter of the invention relates to a tetrapeptide which binds to the ZIP9 receptor for the treatment of osteoporosis, myodegenerative diseases, and male infertility. The invention also relates to the use of the tetrapeptide as a nutritional and feed supplement and to the in-vitro use for growing muscle mass (in-vitro meat production). It is a tetrapeptide consisting of four amino acids which are chemically interlinked by means of peptide bonds, characterised in that it contains the amino acids IAPG (SEQ ID 1) and binds to the androgen receptor ZIP9.

IPC Classes  ?

• A61K 38/07 - Tetrapeptides
• C07K 5/103 - Tetrapeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• A61P 5/26 - Androgens

Abstract

A method for determining contractility independent of load Ees of a ventricle of a person is provided. The chronological profile of blood pressure during isovolumetric contraction (IVK) and isovolumetric relaxation (IVR) is first determined for a at least one ventricle over at least one period of a person's heartbeat. The at least one resulting pressure curve is then calibrated and normalized, and then the end-systolic pressure is determined from this calibrated, normalized pressure curve. The profile of blood volume over time is determined during isovolumetric contraction (IVK) and isovolumetric relaxation (IVR) for a ventricle over at least one period of a person's heartbeat, to determine the end-systolic volume Ves. The intercept VO is then determined from this end-systolic volume Ves, and contractility independent of load Ees of an examined ventricle of a person is calculated as a slope from the end-systolic pressure Pes, the end-systolic volume Ves, and the intercept V0.

IPC Classes  ?

• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• A61B 8/04 - Measuring blood pressure
• A61B 8/06 - Measuring blood flow
• A61B 8/08 - Clinical applications

Abstract

The present invention relates to a comprehensive method for analysing various chemical compounds from samples after performance of at least one metabolism process. The sample is placed on a carrier and various metabolism processes are simulated, e.g. a metabolic process from the human digestive tract from the mouth, stomach and intestine region or the gastrointestinal region. By chromatographic separation, the sample and/or metabolism products are separated and can be detected and analysed individually or jointly. By bringing suspended or adherent cells into contact with the sample or the metabolism products, a conclusion can also be made as to the biological action. The method can be performed quickly, easily and also by means of automation.

IPC Classes  ?

• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
• G01N 30/90 - Plate chromatography, e.g. thin layer or paper chromatography

Abstract

A bacterial strain comprising one or more vectors encoding a) one or more enzymes to produce one or more terpene precursors; and b) a fungal terpene synthase (FTPS). The present invention also relates to a method of producing a terpenoid comprising a) culturing the bacterial strain described herein in an expression medium; and b) isolating the terpenoid from said expression medium.

IPC Classes  ?

• C12N 9/88 - Lyases (4.)
• C12N 9/10 - Transferases (2.)
• C12N 9/90 - Isomerases (5.)
• C12P 5/00 - Preparation of hydrocarbons
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material

Abstract

The invention is concerning a medical preparation comprising bicyclic heptapeptides for use in vertebrates or humans suffering from an infection caused by Gramnegative bacteria like Pseudomonas aeruginosa, Klebsiella pneumoniae, Acineto bacter baumannii, Neisseria gonorrhoeae, Chlamydia trachomatis, Shigella sonnei, Salmonella enterica Typhimurium LT2, Enterobacter spp., Bifidobacterium longum, Bacteroides fragilis, Lactobacillus reuteri, Enterococcus spp., Yersinia pestis and numerous other Gram-negative bacteria.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61P 31/04 - Antibacterial agents
• A61K 38/08 - Peptides having 5 to 11 amino acids

Abstract

The application describes a polycistronic expression cassette comprising two or more coding sequences each separated by a coding sequence encoding a self-cleaving peptides sequence. Self-cleaving peptides cause a ribosomal skipping event allowing a polycistronic translation of two or more coding sequences under the control of a single promoter element. One or more of said coding sequences encode one or more lethal gene product(s) making this expression cassette a lethality system. The expression cassette is under the control of a single repressible promoter. The application also describes an expression construct, which further comprises a second expression cassette. The second expression cassette optionally encodes one or more male determining gene(s). Also, the application describes a transgenic insect comprising this polycistronic expression cassette or expression construct. The transgenic insect is a crop pest insect or a disease transmitting insect. The application also describes the use of a transgenic insect according to the invention for controlling reproduction in an insect population of interest. Furthermore, the application provides a method of controlling reproduction in an insect population of interest.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

The invention relates to an apparatus (10) for producing ion beams of adjustable ion beam profiles. Said apparatus comprises at least one plasma vessel (20) of an ion source with at least two ion optics (25, 26) and an ion optics changer (28). The ion optics changer (28) is designed in such a way that it can move the ion optics (25, 26) between two positions, the ion beam emitted from the plasma vessel of the ion source (20) passing a first ion optics (25) in a first position and alternatively passing a second ion optics (26) in at least one other position.

IPC Classes  ?

• H01J 37/04 - Arrangements of electrodes and associated parts for generating or controlling the discharge, e.g. electron-optical arrangement, ion-optical arrangement
• H01J 37/08 - Ion sourcesIon guns
• H01J 37/147 - Arrangements for directing or deflecting the discharge along a desired path
• F03H 1/00 - Use of plasma to produce a reactive propulsive thrust

Abstract

Agrocybe aegeritaAgrocybe pediadesAgrocybe pediades.

IPC Classes  ?

• C12P 5/00 - Preparation of hydrocarbons
• C12N 15/09 - Recombinant DNA-technology

Abstract

The invention relates to an apparatus for mass-spectrometric analysis and three-dimensional imaging of the surface of a sample, comprising at least one energy source for desorbing and/or ionizing atoms from the surface of a sample, a displacement stage, and a light source. Further, it comprises an interface in order to be able to interchange data with a mass spectrometer such that measurement data can be transmitted from a mass spectrometer to the evaluation unit via the interface such that the chemical composition of the measurement point can be determined by the evaluation unit. The surface of a sample can be captured in three dimensions and the topography of this surface can be determined by the evaluation unit.

IPC Classes  ?

• H01J 49/16 - Ion sourcesIon guns using surface ionisation, e.g. field-, thermionic- or photo-emission
• H01J 49/00 - Particle spectrometers or separator tubes
• H01J 49/40 - Time-of-flight spectrometers

Abstract

The invention relates to a zinc electrode (1) for use in a zinc-oxygen battery or NiOOH-zinc battery, comprising a first layer (20) of zinc and/or zinc oxide. The carbon electrode (1) further has a second layer (30), which is designed such that it can be used as an anion exchanger and is also permeable to OH- ions.

IPC Classes  ?

• H01M 4/24 - Electrodes for alkaline accumulators
• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 12/06 - Hybrid cellsManufacture thereof composed of a half-cell of the fuel-cell type and of a half-cell of the primary-cell type with one metallic and one gaseous electrode
• H01M 12/08 - Hybrid cellsManufacture thereof composed of a half-cell of a fuel-cell type and a half-cell of the secondary-cell type
• H01M 10/30 - Nickel accumulators

Abstract

The invention relates to nanoparticles for the administration of the active ingredient by inhalation, the active ingredient being selected from the list comprising paclitaxel, docetaxel and SB-T-1214, comprising PLGA, PVA, TPGS, PLA, and for the treatment of pulmonary hypertension. The particles are distinguished by a high degree of loading and high stability in the process of nebulization by means of a nebulizing device.

IPC Classes  ?

• A61K 9/50 - Microcapsules
• A61K 9/51 - Nanocapsules

Abstract

The present invention relates to a method for producing a vitamin- and protein-rich product, to a food product containing the vitamin- and protein-rich product, and to a nutrient medium appropriate for said method on the basis of agricultural tributaries or food tributaries.

IPC Classes  ?

• C12N 1/14 - Fungi Culture media therefor
• C12N 1/20 - BacteriaCulture media therefor
• C12P 39/00 - Processes involving microorganisms of different genera in the same process, simultaneously
• C12P 19/42 - Cobalamins, i.e. vitamin B12, LLD factor

Abstract

The invention relates to an apparatus for mass-spectrometric analysis and three-dimensional imaging of the surface of a specimen, comprising at least one energy source 20 for desorbing and/or ionizing atoms on the surface of a specimen, a displacement stage 1, and a light source 8, 10. Moreover, it comprises a control unit 30 for controlling the displacement stage 1 in such a way that the surface of a specimen can be irradiated in a punctiform manner by the energy source 20, 10 and the light source 8, 10, either step-by-step or in a continuous movement. Further, it comprises an interface 50 in order to be able to interchange data with a mass spectrometer such that measurement data from a mass spectrometer can be transmitted via the interface 50 to the evaluation unit, and so the chemical composition of the measurement point 60 can be determined by the evaluation unit 40. Further, it comprises an optical system 3, a light detector 4 and an evaluation unit 40. Here, the light source 8, 10, the optical system 3 and the light detector 4 interact in such a way that a measurement point 60 can be produced on a specimen by the light source 8, 10 by way of an optical system and light that is reflected or scattered by the measurement point 60 can be captured by the light detector 4 with an optical system 3 disposed upstream thereof. Hence, it is possible to capture the surface of a specimen in three dimensions and the topography of this surface can be determined by the evaluation unit 40.

IPC Classes  ?

• H01J 49/00 - Particle spectrometers or separator tubes
• H01J 49/16 - Ion sourcesIon guns using surface ionisation, e.g. field-, thermionic- or photo-emission

Abstract

The invention describes a new method for in vivo measurement and control of intraocular VEGF concentration using bioluminescence resonance energy transfer (BRET) of a VEGF-binding biosensor. Furthermore, the method is suitable for highly sensitive in vitro determination of VEGF concentration from a small sample volume.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 49/00 - Preparations for testing in vivo
• G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching

Abstract

The technology provided herein relates to methods of multi-species insect pest control by incorporating an inhibitor against the structural sheath protein (SHP) into the body of an agricultural target pest, and to pest control agents to be used in the method and to transgenic crop, greenhouse and ornamental plants.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• A01N 63/10 - AnimalsSubstances produced thereby or obtained therefrom
• A01N 57/16 - Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-oxygen bonds or phosphorus-to-sulfur bonds containing heterocyclic radicals
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A01N 61/00 - Biocides, pest repellants or attractants, or plant growth regulators containing substances of unknown or undetermined composition, e.g. substances characterised only by the mode of action
• A01N 65/00 - Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof

Abstract

The present invention relates to a Statistical method of assessing whether a subject suffers from Cancer or is prone to suffering from Cancer, said method comprising the step of performing at least one Statistical algorithm for Classification and for regression on measurement data of the subject, wherein the measurement data of the subject comprises at least one of the following: a value of GATA6 Em isoform in at least one sample taken from the subject, a value NKX2-1 Em isoform in said at least one sample, a value of GATA6 Ad isoform in said at least one sample, NKX2-1 Ad isoform in said at least one sample; and wherein at least one of the following is used as at least one classifier or a component of at least one classifier in the Statistical method: GATA6 Em isoform, NKX2-1 Em isoform, GATA6 Ad isoform, NKX2-1 Ad isoform, ratio of GATA6 Em isoform / GATA6 Ad isoform, ratio of NKX2- 1 Em isoform / NKX2-1 Ad isoform.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The invention relates to an ion drive for a spacecraft, in particular for a satellite, comprising a reservoir with fuel; an ionization chamber connected to the reservoir; a generator for producing an electrostatic, magnetostatic and/or electromagnetic field the interior of the ionization chamber, wherein the field is suitable for ionizing the fuel; and a charge-carrier acceleration system for producing an electric field suitable for accelerating the ionized fuel, wherein the fuel contains a diamondoid. Moreover, the invention relates to a spacecraft comprising an ion drive, a method for operating an ion drive and the use of diamandoid as fuel for an ion drive.

IPC Classes  ?

• F03H 1/00 - Use of plasma to produce a reactive propulsive thrust

Abstract

The invention relates to a coating of glass with thermochromic vanadium dioxide. The coloration of the vanadium dioxide is shifted from bronze to neutral (colorless) by a doping with alkaline earth metals, for example Ca, Sr and Br. The thermochromic effect is maintained at the same time.

IPC Classes  ?

• B32B 9/00 - Layered products essentially comprising a particular substance not covered by groups
• B32B 13/00 - Layered products essentially comprising a water-setting substance, e.g. concrete, plaster, asbestos cement, or like builders' material
• B32B 19/00 - Layered products essentially comprising natural mineral fibres or particles, e.g. asbestos, mica
• C03C 17/06 - Surface treatment of glass, e.g. of devitrified glass, not in the form of fibres or filaments, by coating with metals
• C03C 17/34 - Surface treatment of glass, e.g. of devitrified glass, not in the form of fibres or filaments, by coating with at least two coatings having different compositions
• C03C 17/245 - Oxides by deposition from the vapour phase
• C23C 14/34 - Sputtering
• H01L 31/0216 - Coatings
• C09K 9/00 - Tenebrescent materials, i.e. materials for which the range of wavelengths for energy absorption is changed as a result of excitation by some form of energy

Abstract

The invention relates to an atomizer system 100 comprising a spray head and a spray chamber 18 that can be gas-sealingly connected to the spray head. In a part facing the spray chamber 18 the spray head 1 has a tapered portion forming a nozzle 17 for atomizing liquid with gas. The spray head 1 thus has a two-phase nozzle with internal mixing.

IPC Classes  ?

• B05B 7/04 - Spray pistolsApparatus for discharge with arrangements for mixing liquids or other fluent materials before discharge
• B05B 15/12 - Spray booths
• B05B 17/04 - Apparatus for spraying or atomising liquids or other fluent materials, not covered by any other group of this subclass operating with special methods
• F15D 1/08 - Influencing the flow of fluids of jets leaving an orifice
• B05D 1/02 - Processes for applying liquids or other fluent materials performed by spraying
• B05B 7/12 - Spray pistolsApparatus for discharge designed to control volume of flow, e.g. with adjustable passages

Abstract

The invention relates to the use of esters of saturated short- and medium-chain fatty acids for the prophylaxis and therapy of diseases and cosmetic problems in humans and animals caused or sustained involving Malassezia yeasts.

IPC Classes  ?

• A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
• A61P 17/00 - Drugs for dermatological disorders
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The technology provided herein relates to methods of multi-species insect pest control by incorporating an inhibitor against the structural sheath protein (SHP) into the body of an agricultural target pest, and to pest control agents to be used in the method and to transgenic crop, greenhouse and ornamental plants.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• A01N 61/00 - Biocides, pest repellants or attractants, or plant growth regulators containing substances of unknown or undetermined composition, e.g. substances characterised only by the mode of action

Abstract

The present invention relates to a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer, comprising the measurement of the amounts of specific isoforms of GATA6 and/or NKX2-1 in a sample of said subject. Furthermore, the present invention relates to a composition for use in medicine comprising (an) inhibitor(s) of specific isoforms of GATA6 and/or NKX2-1. Additionally, the present invention relates to a kit for use in a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The invention relates to gas sensors and in particular a gas sensor system comprising a plurality of gas sensor elements, having the possibility of simultaneously detecting a plurality of different gases. The gas sensors, which are of a new type, combined in a gas sensor system, enable the simultaneous detection of different gases while the media separation is maintained between the detection and evaluation unit and the sensor chip for use in chemically aggressive or explosive gases or gas mixtures. In particular, semiconductor nanostructures that emit photoluminescence (PL) are used as sensor elements.

IPC Classes  ?

• G01N 21/64 - FluorescencePhosphorescence
• B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour

Abstract

Inhalation is one of the most important methods of administration of active ingredients, for example in the treatment of respiratory disorders or in anaesthesia. A disadvantage of the current prior art is that not all solutions or suspensions can be nebulized with a standard nebulizer so as to result in a particle size distribution suitable for inhalation treatment in the aerosol produced. The invention therefore relates to a method for nebulizing a solution or colloid to form aerosol particles, wherein the solution or colloid contains at least one additive, the additive being a low molecular weight compound or a polyether or a polysorbate or a modified PVA, and aerosol-physical parameters of the particles formed by nebulization of the solution or colloid are adjusted via the concentration of the additive in the solution or of the colloid. The invention further relates to an aerosol obtainable by this method for pulmonary administration in a patient for diagnosis or treatment of a disorder.

IPC Classes  ?

• A61K 47/02 - Inorganic compounds
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

The invention relates to an optical pH value sensor having a nanowire structure and applied electrochemical potential, wherein the photoluminescence intensity of the nanowires is detected in a spatially resolved manner and then the pH values are determined by means of the calibration data.

IPC Classes  ?

• G01N 27/416 - Systems
• G01N 27/414 - Ion-sensitive or chemical field-effect transistors, i.e. ISFETS or CHEMFETS
• G01N 21/64 - FluorescencePhosphorescence
• G01N 21/80 - Indicating pH value
• B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator

Abstract

The molecule NAD and the diastereomer thereof ß-NAD have a muscle-relaxant effect on the musculature of the airways, particularly on the bronchial musculature. Therefore NAD and the diastereomer thereof ß-NAD open up a new approach for the therapy and prophylaxis of a number of diseases, disorders and conditions in which the concentration of free calcium in the muscle cells of the airway musculature is abnormally changed. Consequently, a suitable pharmaceutical preparation with the active ingredient NAD or the diastereomer thereof ß-NAD is provided as a medicine against diseases which are accompanied by a constriction of the airway musculature.

IPC Classes  ?

• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61P 11/06 - Antiasthmatics
• A61P 11/08 - Bronchodilators

Abstract

The development relates to coating glass with thermochromic vanadium dioxide. The coloration of the vanadium dioxide is shifted from bronze to neutral (colourless) by doping with earth-alkaline elements, e.g. Ca, Sr, Ba. At the same time, the thermochromic effect is maintained.

IPC Classes  ?

• C03C 17/34 - Surface treatment of glass, e.g. of devitrified glass, not in the form of fibres or filaments, by coating with at least two coatings having different compositions

Abstract

The present invention relates to compounds derived from steroids of the general formula (I) # represents a steroid residue, the use of compounds of the general formula (I) in medicine and for the prophylaxis and/or the treatment of infectious diseases. Furthermore described are pharmaceutical compositions containing at least one compound of the general formula (I). A further aspect of the invention relates to the synthesis of said compounds of the general formula (I).

IPC Classes  ?

• C07J 11/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 3
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07J 41/00 - Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring

Abstract

The present invention relates to heterojunctions, more particularly for use as p-n diodes, the production thereof, and photovoltaic solar cells built therefrom. The heterojunction has Cu20, Cu403 or CuO, which forms the p-type part of the diode as an absorber layer. The n-type part of the diode has (Al, In)GaN in a Cu2O absorber layer, and/or (Al, In)GaN or ZnO-based systems (such as MgZnO, BeZnO) in Cu4O3 and CuO absorber layers. These p-type and n-type parts can form a tandem solar cell. Cu2O, Cu4O3 and/or CuO are produced by means of a sputtering process using an oxygen flow in plasma.

IPC Classes  ?

• H01L 31/0336 - Inorganic materials including, apart from doping materials or other impurities, semiconductor materials provided for in two or more of groups in different semiconductor regions, e.g. Cu2X/CdX hetero-junctions, X being an element of Group VI of the Periodic System
• H01L 31/072 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof adapted as photovoltaic [PV] conversion devices characterised by at least one potential-jump barrier or surface barrier the potential barriers being only of the PN heterojunction type
• H01L 31/0725 - Multiple junction or tandem solar cells

Abstract

The invention relates to a tin-enriched adhesive system for treating hypersensitive teeth and for bonding composites and ceramics to the hard tooth tissue, in particular for improved adhesion of composites, ceramics, and other dental materials on teeth that have previously experienced erosion and coating materials specifically indicated for erosion/tooth wear.

IPC Classes  ?

• A61K 6/00 - Preparations for dentistry

Abstract

The present invention provides methods for treating interstitial lung diseases, comprising administering to an individual an effective amount of an inhibitor of coagulation factor XII. The invention further provides uses and pharmaceutical kits for that treatment.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/81 - Protease inhibitors
• A61K 38/55 - Protease inhibitors
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The invention describes chimeric nucleases consisting of a DNA binding site derived from a TALE protein, a linker, and a cleavage module derived from a restriction endonuclease which are used for gene targeting efforts. The chimeric nucleases according to the invention exhibit increased preference and specificity to bipartite or tripartite DNA target sites comprising TALE recognition site(s) and restriction endonuclease target site while cleaving at off-target sites comprising only the restriction endonuclease target site is prevented.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

A process for producing a beverage or a beverage base, in which a medium is fermented in at least one fermentation process, in which the medium is pumpable, and in which the fermentation process is performed aerobically, the medium being fermented by mycelium of at least one basidiomycete.

IPC Classes  ?

• A23L 2/00 - Non-alcoholic beveragesDry compositions or concentrates thereforPreparation or treatment thereof
• C12C 11/00 - Fermentation processes for beer
• C12G 3/00 - Preparation of other alcoholic beverages
• C12G 3/02 - Preparation of other alcoholic beverages by fermentation

Abstract

The present invention provides bio-compatible nano-polymer particles which consist of a bio-compatible polymer, a stabiliser and an active ingredient for the treatment of pulmonary hypertension or erectile dysfunction and can be used to produce an agent for the treatment of pulmonary hypertension or erectile dysfunction.

IPC Classes  ?

• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

The present invention provides stabilisers for coating bio-compatible nano and microparticles, said stabilisers preventing particles from aggregating during production and storage, as well as before and during nebulisation. The stabilisers can be used to produce an agent for pulmonary application.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 9/12 - AerosolsFoams

Abstract

The invention relates to a device and to a method for obtaining sperm from animals, in particular from birds such as parrots.

IPC Classes  ?

• A61D 19/02 - Instruments or methods for reproduction or fertilisation for artificial insemination

Abstract

The invention relates to steroid-derived compounds of general formula (I) wherein L is a linker and R# is a steroid group, and to the use of the compounds of general formula (I) in medicine and for the prophylaxis and/or treatment of infectious diseases. The invention also relates to pharmaceutical compositions containing at least one compound of general formula (I), and to the synthesis of the compounds of general formula (I).

IPC Classes  ?

• C07J 41/00 - Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61P 31/04 - Antibacterial agents
• A61P 31/10 - Antimycotics
• A61P 31/12 - Antivirals
• A61P 33/00 - Antiparasitic agents

Abstract

The present invention relates to tripodal catechol derivatives having a flexible basic framework for functionalizing surfaces, to methods for the production and to the use thereof. The central atom of the flexible frameworks is a tertiary aliphatic carbon atom. The remaining fourth bridgehead position can easily be further functionalized further by so-called click reactions, for example by using biomolecules, dyes, radio markers, polyethylene glycol or active substances. The compounds according to the invention have the general formula X-C[(CH2)n-YZ]3, wherein X represents a group -(CH2)p-R5, in which p = 0-10 and R5 is selected from -H, -NH2, -NO2, -OH, -SH, -O-NH2, -NH-NH2, -N=C=S-, -N=C=O-, -CH=CH2, -C=CH, -COOH, -(C=O)H, -(C=O)R6, Y represents -CH2-, -CH=CH-, -C=C-, -O-, -S-, -S-S-, -NH-, -O-NH-, -NH-O-, -HC=N-O-, -O-N=CH-, -NR1-, -aryl-, -heteroaryl-, -(C=O)-, -O-(C=O)-, -(C=O)-O-, -NH-(C=O)-, -(C=O)-NH-, -NR1-(C=O)-, -(C=O)-NR1-, -NH-(C=O)-NH-, -NH-(C=S)-NH-, R1 represents an alkyl group, R6 represents an alkyl, alkenyl, alkinyl, aryl or heteroaryl group and Z represents a catechol derivative. The compounds are produced by reacting a compound X-C[(CH2)n-Y']3 with a reagent Y"Z to form the corresponding compound X-C[(CH2)n-YZ]3 and the reaction product is subsequently purified. Y' and Y'' are precursors of Y. The compounds according to the invention of formula (I) can be used in a method for functionalizing surfaces. Optionally, the group X of the compounds according to the invention can be coupled to an effector, for example by means of click chemistry.

IPC Classes  ?

• C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
• C07C 235/32 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings

Abstract

The present invention relates to tripodal catechol derivatives having an adamantyl basic framework for functionalizing surfaces, to methods for the production and to the use thereof. The remaining fourth bridgehead position can easily be further functionalized by so-called click reactions, for example by using biomolecules, dyes, radio markers, polyethylene glycol or active substances. The compounds according to the invention have the general formula X-Ad[(CH2)n-YZ]3, wherein Ad represents the adamantyl basic framework, X represents a group -(CH2)p-R5, in which p = 0-10 and R5 is selected from -H, -NH2, -NO2, -OH, -SH, -O-NH2, -NH-NH2, -N=C=S-, -N=C=O-, -CH=CH2, -C=CH, -COOH, -(C=O)H, -(C=O)R6, Y represents -CH2-, -CH=CH-, -C=C-, -O-, -S-, -S-S-, -NH-, -O-NH-, -NH-O-, -HC=N-O-, -O-N=CH-, -NR1-, -aryl-, -heteroaryl-, -(C=O)-, -O-(C=O)-, -(C=O)-O-, -NH-(C=O)-, -(C=O)-NH-, -NR1-(C=O)-, -(C=O)-NR1-, -NH-(C=O)-NH-, -NH-(C=S)-NH-, R1 represents an alkyl group, R6 represents an alkyl, alkenyl, alkinyl, aryl or heteroaryl group and Z represents a catechol derivative. The compounds are produced by reacting a compound X-Ad[(CH2)n-Y']3 with a reagent Y"Z to form the corresponding compound X-Ad[(CH2)n-YZ]3 and the reaction product is subsequently purified. Y' and Y'' are precursors of Y. The compounds according to the invention of formula (I) can be used in a method for functionalizing surfaces. Optionally, the group X of the compounds according to the invention can be coupled to an effector, for example by means of click chemistry.

IPC Classes  ?

• C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
• C07C 235/46 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

Abstract

The present invention relates to tripodal bisphosphonate derivatives having an adamantyl basic framework for functionalizing surfaces, to methods for the production and to the use thereof. The remaining fourth bridgehead position of the adamantane framework can optionally be functionalized by so-called click reactions, for example by using biomolecules, polyethylene glycol or active substances. The compounds according to the invention have the general formula X-Ad{(CH2)n-Y-C[PO(OH)2]2R1}3, wherein Ad represents the adamantyl framework, X represents a group -(CH2)p-R3, in which p = 0-10 and R3 is selected from -H, -NH2, -NO2, -OH, -SH, -O-NH2, -NH-NH2, -N=C=S-, -N=C=O-, -CH=CH2, -C=CH, -COOH, -(C=O)H, -(C=O)R4, Y represents -CH2-, -CH=CH-, -C=C-, -O-, -S-, -S-S-, -NH-, -O-NH-, -NH-O-, -HC=N-O-, -O-N=CH-, -NR2-, -aryl-, -heteroaryl-, -(C=O)-, -O-(C=O)-, -(C=O)-O-, -NH-(C=O)-, -(C=O)-NH-, -NR2-(C=O)-, -(C=O)-NR2-, -NH-(C=O)-NH-, -NH-(C=S)-NH-, R1 represents a hydrogen atom or a hydroxy group, R2 represents a linear or branched alkyl group, and R4 represents a linear or branched alkyl or aryl group. The compounds are produced by reacting a compound X-Ad[(CH2)n-Y']3 with a reagent Y"C[PO(OH)2]2R1 to form the corresponding compound X-Ad{(CH2)n-Y-C[PO(OH)2]2R1}3 and the reaction product is subsequently purified. Y' and Y'' are precursors of Y. The compounds according to the invention of formula (I) can be used in a method for functionalizing surfaces. Optionally, the group X of the compounds according to the invention can be coupled to an effector, for example by means of click chemistry.

IPC Classes  ?

• C07F 9/38 - Phosphonic acids [R—P(:O)(OH)2]Thiophosphonic acids

Abstract

The present invention relates to tripodal bisphosphonate derivatives having a flexible basic framework for functionalizing surfaces, to methods for the production and to the use thereof. The central atom of the flexible frameworks is a tertiary aliphatic carbon atom. A remaining fourth bridgehead position of the flexible framework can optionally be functionalized by so-called click reactions, for example by using biomolecules, polyethylene glycol or active substances. The compounds according to the invention have the general formula X-C{(CH2)n- Y-C[PO(OH)2]2R1}3, wherein X represents a group -(CH2)p-R3, in which p = 0-10 and R3 is selected from -H, -NH2, -NO2, -OH, -SH, -O-NH2, -NH-NH2, -N=C=S-, -N=C=O-, -CH=CH2, -C=CH, -COOH, -(C=O)H, -(C=O)R4, Y represents CH2-, -CH=CH-, -C=C-, -O-, -S-, -S-S-, -NH-, -O-NH-, -NH-O-, -HC=N-O-, -O-N=CH-, -NR2-, -aryl-, -heteroaryl-, -(C=O)-, -O-(C=O)-, -(C=O)-O-, -NH-(C=O)-, -(C=O)-NH-, -NR2-(C=O)-, -(C=O)-NR2-, -NH-(C=O)-NH-, -NH-(C=S)-NH-, R1 represents a hydrogen atom or a hydroxy group, R2 represents a linear or branched alkyl group, and R4 represents a linear or branched alkyl or aryl group. The compounds are produced by reacting a compound X-C[(CH2)n-Y']3 with a reagent Y"C[PO(OH)2]2R1 to form the corresponding compound X-C{(CH2)n-Y-C[PO(OH)2]2R1}3 and the reaction product is subsequently purified. Y' and Y'' are precursors of Y. The compounds according to the invention of formula (I) can be used in a method for functionalizing surfaces. Optionally, the group X of the compounds according to the invention can be coupled to an effector, for example by means of click chemistry.

IPC Classes  ?

• C07F 9/38 - Phosphonic acids [R—P(:O)(OH)2]Thiophosphonic acids

Abstract

The invention relates to a method for producing a p-conductive semiconductor layer containing ZnO, comprising the supply of a gaseous nitrogen/hydrogen compound to a reactor during the deposition of the semiconductor layer (S32) containing ZnO, the adsorption of the nitrogen/hydrogen compound on a respective current growth surface of the semiconductor layer (S34) containing ZnO, and the formation of a nitrogen/hydrogen complex in the semiconductor containing ZnO as an acceptor structure which effects p-conductivity using the adsorbed nitrogen/hydrogen compound (S36).

IPC Classes  ?

• H01L 21/02 - Manufacture or treatment of semiconductor devices or of parts thereof
• H01L 21/20 - Deposition of semiconductor materials on a substrate, e.g. epitaxial growth

Abstract

The invention comprises peptide or non-peptide receptor agonists of the natriuretic system, preferably NPRA and NPRB receptor agonists for the prevention and/or therapy of disease conditions which are accompanied by increased extracellular liquid volume and in which the second messenger cGMP develops protective properties and in which an anti-hypertrophic (antifibrotic) effect is desired. The invention in particular relates to peptide or non-peptide receptor agonists of the natriuretic system for treating congestive heart disease, coronary heart disease, organ and functional vascular disorders, nephrotic syndrome, high blood pressure, myocardial infarction, acute pulmonary damage, erectile dysfunction, primary or secondary fibrosis, cirrhosis of the liver, pulmonary fibrosis or for improving blood circulation of the arteries, veins and capillaries.

IPC Classes  ?

• A61K 38/22 - Hormones
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

The invention relates to biocompatible nano-, meso-, and micro-polymer particles which can bind pathogenic proteins that penetrate into the lining layer of the lung. Known pathogenic proteins in the pulmonary lining layer are negatively charged. Said proteins damage the pulmonary surfactant system, which is essential for maintaining a low surface tension in the lung and thus for functional breathing. Polymer particles according to the invention have a diameter between 20 nm and 10 pm, are water-insoluble, and have a positive surface charge and a low surface hydrophobicity. The isoelectric point of the particles is greater than 5, so that the particles are present in the lining layer of the lung as positively charged particles, and also greater than the isoelectric point of the pathogenic proteins to be bound. The polymer particles according to the invention can be produced by means of precipitation or emulsion methods for example. The polymer particles according to the invention can be used for maintaining a low surface tension in the lung and for protecting the pulmonary surfactant.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/51 - Nanocapsules
• A61K 31/78 - Polymers containing oxygen of acrylic acid or derivatives thereof
• A61K 31/785 - Polymers containing nitrogen
• C08L 33/14 - Homopolymers or copolymers of esters of esters containing halogen, nitrogen, sulfur, or oxygen atoms in addition to the carboxy oxygen

Abstract

The invention relates to the use of NOS inhibitors, such as L-NIL, for producing an agent for treating and/or preventing chronic pulmonary diseases in humans.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 11/06 - Antiasthmatics
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The disclosed invention relates to peptides incorporating 3-aminoadamantane-1-carboxylic acids. These peptides are disclosed as surprisingly possessing neurogenic and neurotrophic properties. These pharmacological activities can advantageously be utilized for restoring or maintaining neuronal function in the CNS. In particular, the compounds can be used for treatment and prophylaxis of neurodegenerative diseases, e. g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, as well as in post-acute traumatic brain injury, or cerebral ischemia.

IPC Classes  ?

• C07K 7/02 - Linear peptides containing at least one abnormal peptide link
• C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to a method and an apparatus for determining the concentration of protamine 1 and protamine 2 and the ratio of protamine 1 to protamine 2 as a protamine/protein ratio in a questionable sample from an individual to be examined in vitro in order to determine the fertility of sperm. This is very important for the prognosis for the success of artificial insemination of an egg cell in vitro. The test strip has a sperm pretest for determining the sperm concentration and a protamine rapid test for determining the concentration of protamine 1 and protamine 2 and the ratio of protamine 1 to protamine 2 as a protamine/protein ratio.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/558 - ImmunoassayBiospecific binding assayMaterials therefor using diffusion or migration of antigen or antibody
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention pertains to an inhibitor molecule that is capable of inhibiting the activity of miR17, miR21 or miR92a in a cell for the purpose of treating pulmonary hypertension as well as to a pharmaceutical composition for treating pulmonary hypertension.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides

Abstract

The present invention relates to a method for the diagnosis, early detection and/or risk stratification of pulmonary hypertonism in a patient and/or monitoring a therapy of such a disease in a patient, comprising the quantitative determination of at least one component of the vascular endothelial growth factor (VEGF) signal pathway as biomarker, in particular the quantitative determination of the biomarkers soluble Fms-like tyrosine kinase-1 (sFlt) and/or placental growth factor (PIGF). The invention furthermore relates to a diagnostic kit for carrying out the method according to the invention, and to its use.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention provides methods for treating interstitial lung diseases, comprising administering to an individual an effective amount of an inhibitor of coagulation factor XII. The invention further provides uses and pharmaceutical kits for that treatment.

IPC Classes  ?

• C07K 14/81 - Protease inhibitors
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention relates to a device for spreading active agricultural agents, wherein the device can be brought to the site of action temporally and spatially separated from the production process and comprises a dispenser as well as non-water-soluble nanofibers and/or mesofibers storing active agricultural agents. The polymers of which the nanofibers or mesofibers consist are preferably biodegradable. The active agricultural agents are selected from the group consisting of fungicides, herbicides, bactericides, plant growth regulators and plant nutrients. They are preferably pheromones, kairomones, and signal substances. The invention further discloses a method for producing said device, wherein the nanoparticles and/or mesofibers storing active agents are produced by means of electrospinning. The device can be used to bring active agricultural agents to the site of action thereof temporally and spatially separated from the production process. The spreading can be done mechanically or automatically. The site is preferably a useful area from pomiculture, viticulture, horticulture or a commercial row crop. The device according to the invention is particularly suited for controlling arthropods.

IPC Classes  ?

• D01F 1/10 - Other agents for modifying properties
• D01F 6/84 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof from copolycondensation products from copolyesters
• D01D 5/00 - Formation of filaments, threads, or the like
• A01N 25/10 - Macromolecular compounds
• A01N 25/34 - Shaped forms, e.g. sheets, not provided for in any other group of this main group
• A01G 13/02 - Protective coverings for plants; Devices for laying-out coverings

Abstract

The current invention relates to a method of making metal oxide nanoparticles comprising the reaction of - at least one metal oxide precursor (P) containing at least one metal (M) with - at least one monofunctional alcohol (A) wherein the hydroxy group is bound to a secondary, tertiary or alpha-unsaturated carbon atom - in the presence of at least one aliphatic compound (F) according to the formula Y1-R1-X-R2-Y2, wherein - R1 and R2 each are the same or different and independently selected from aliphatic groups with from 1 to 20 carbon atoms, - Y1 and Y2 each are the same or different and independently selected from OH, NH2 and SH, and - X is selected from the group consisting of chemical bond, -O-, -S-, -NR3-, and CR4R5, wherein R3, R4 and R5 each are the same or different and represent a hydrogen atom or an aliphatic group with from 1 to 20 carbon atoms which optionally carries functional groups selected from OH, NH2 and SH. This invention also relates to metal oxide nanoparticles, to a method of making dispersions of said nanoparticles and to dispersions containing them.

IPC Classes  ?

• C01G 1/02 - Oxides
• C01G 15/00 - Compounds of gallium, indium, or thallium
• C01G 19/02 - Oxides
• C01G 21/02 - Oxides
• C01G 23/047 - Titanium dioxide
• C01G 25/02 - Oxides
• C01G 30/00 - Compounds of antimony
• C01G 31/02 - Oxides
• C01G 33/00 - Compounds of niobium
• C01G 35/00 - Compounds of tantalum
• C01G 37/02 - Oxides or hydrates thereof
• C01G 45/02 - Oxides
• C01G 49/02 - OxidesHydroxides

Abstract

The invention relates to liposomes for pulmonary application, advantageously comprising at least one first and at least one second phospholipid, cholesterol, and at least one active substance and/or colorant, wherein the first phospholipid is a phosphatidylcholine, preferably DSPC, and the second phospholipid is a phosphatidylcholine or an ethanolamine, preferably selected from the group DMPC, DPPC, DPPE. It is thereby advantageous if the first and the second phospholipid are present at a molar ratio of 0.5:1 to 10:1, preferably at a ratio of 6:1 to 2:1, in particular preferably at a ratio of 3:1. It is further advantageous if the molar ratio between phospholipids and cholesterol is between 10:1 and 1:1, preferably between 6:1 and 3:1, in particular preferably 4:1. The second phospholipid is further preferably DMPC or DPPE, in particular preferably DPPE. The size of the liposomes is advantageously between 0.05 µm and 5 µm, preferably between 0.2 µm and 2.0 µm, and the median aerodynamic mass diameter of aerosol particles comprising the liposomes is between 1 µm and 6 µm, preferably between 1.5 µm and 5 µm, in particular preferably between 2 µm and 4.5 µm. It is further in particular advantageous if the liposomes comprise an atomization stability of greater than 50%, preferably greater than 75%, in particular preferably greater than 80%, and if the transition temperature is greater than 37 °C, preferably greater than 45 °C, in particular preferably greater than 50 °C.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Abstract

The invention relates to a novel method and a novel device for annealing scintillation crystals that reduces the damage thereto by effect of radiation in terms of a reduction of the optical transparency. For the first time, such damage has been completely healed quasi on-line, i.e. at the same time as the damage occurred, so that reduction of the optical transparency is no longer observable during the operation of said crystals.

IPC Classes  ?

• G01T 1/202 - Measuring radiation intensity with scintillation detectors the detector being a crystal

Abstract

The present invention relates to a device and a method for removing, producing, storing, and transporting blood products in the widest sense, in particular a closed blood removal, processing, and storage system, and a system for administering drugs that are obtained from blood or blood products and a corresponding method for obtaining, producing, storing, and transporting blood products or blood components or blood constituents or blood preparations (within the meaning of the Medical Products Act AMG) in a legally compliant and GMP-compliant manner. In an exceptional manner, the present invention enables the production, storage, transport, and administration of completely aliquoted autologous serum eye drops or other drugs from blood or blood products that can be applied to the patient directly without the need for clean-room laboratories.

IPC Classes  ?

• A61M 1/02 - Blood transfusion apparatus
• A61J 3/00 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms

Abstract

The invention relates to composite materials comprising polymer nanofibers and polymer nanoparticles, wherein at least one of the two polymer materials is loaded with a substance selected from therapeutic and diagnostic agents. Fibers and nanoparticles can comprise identical or different polymers; the polymer materials are, however, biocompatible in every case. Therapeutic and diagnostic agents can be hydrophilic or lipophilic and the two polymer materials likewise. The at least one polymer material and the substance with which said material is loaded are either both hydrophilic or both lipophilic. The polymer nanoparticles of the composite materials have a diameter of 10 nm to 600 nm. The polymer fibers have diameters of 10 nm to 50 µm and lengths of 1 µm to several meters. The invention further relates to a method for producing said composite materials. Polymer nanoparticles can be produced in different ways, such as through controlled precipitation of a polymer solution that optionally comprises a loading substance. The nanoparticles are then mixed with another polymer and a loading substance as applicable, depending on whether particles, fibers or both are to be loaded with substance. The processing of this solution into composites comprising polymer fibers polymer nanoparticles can occur by means of electrospinning, melt spinning, extruding or template process. Composite materials according to the invention are suitable for the production of pharmaceuticals that release therapeutically or diagnostically effective substances slowly and in a controlled manner.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 9/70 - Web, sheet or filament bases

Abstract

The invention relates to an occlusion implant (1) for occluding a blood vessel (19). The implant (1, 24) comprises a wire (5) that is wound to form a helical coil (2, 3, 25, 29). The coil has a first pitch over wide areas (7). However, in at least one second area (9), the coil (2, 3, 25, 29) has a second pitch that differs from the first pitch.

IPC Classes  ?

• A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord

Abstract

The present invention relates to an agent for the prophylaxis and treatment of pityriasis. The agent according to the invention comprises at least one transaminase inhibitor that effectively inhibits the development of the transamination process that is pathogenetically significant to the disease, prevents a recurrence of the disease, and is easy on the skin flora of humans. Upon entry into the environment, resistances are not induced in other fungi.

IPC Classes  ?

• A61K 31/15 - Oximes (C=N—O—)Hydrazines (N—N)Hydrazones (N—N=)
• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
• A61K 31/42 - Oxazoles
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/7008 - Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61P 17/00 - Drugs for dermatological disorders
• A61P 31/10 - Antimycotics

Abstract

The invention relates to the use of ribosomal protein S19 (symbol: RPS19, HGNC ID:10402, alias: DBA), which inhibits the proinflammatory and procarcinogenic effects of MIF, as a material for producing a means for treating acute and chronic inflammatory diseases and cancer diseases.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

The invention relates to nucleic acid molecules encoding peptides which interact with autoantibodies associated with Complex Regional Pain Syndrome, to the peptides themselves, to a pharmaceutical composition comprising said nucleic acid molecules and peptides, and to the use of said peptides - especially in apheresis and in vitro assays- for the treatment and the diagnosis of Complex Regional Pain Syndrome.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention relates to an immunological test for detecting and for specifically determining autoantibodies against testicular antigens that accompany inflammatory fertility disorders of male mammals in a biological sample of a male mammal, particularly for detecting testicular ER-60 autoantibodies and/or transferrin autoantibodies. The immunological test is used to determine the presence of immunological and infection-related infertility of male mammals, particularly of humans.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12N 9/90 - Isomerases (5.)

Abstract

The invention relates to a method for the specific and early detection of a Mycobacterium avium ssp. paratuberculosis (MAP) infection in a biological sample of a mammal by detecting cells producing interferon-gamma (IFN-γ) after incubating peripheral blood mononuclear cell cultures (PBMC) with MAP antigen preparations or Mycobacterium avium ssp. avium (MAA) and/or Mycobacterium phlei (M. phlei) control antigens.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a method and a test kit for the specific and sensitive detection of antibodies against Mycobacterium avium ssp. paratuberculosis (MAP) in biological samples. The method and the test kit are also used to detect antibodies against Mycobacterium tuberculosis or Mycobacterium bovis.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The invention relates to functionalised diols of diamondoids wherein one of the two hydroxy groups is masked by a protective group, and to methods for producing said functionalised diols. The protective group is a -CHR1R2 group, wherein R1 and R2 are alkyl groups. The protective group contains at least one halogen atom. The monoethers of the diamondoid diols are produced by reacting the diamondoid diol with a halogenated alcohol CHOHR1R2 in the presence of a catalyst acid. The monoetherified diols enable the targeted production of derivatives of the diamondoids, for example the corresponding amino alcohols and aminocarboxylic acids. To this end, the diamondoid monoether is reacted with a halogenonitrile in a Ritter reaction, in a first step, to form the corresponding monoether amide. The corresponding amino alcohol is produced from said monoether amide by reacting the protective group -CHR1R2 first with trifluoroacetic acid to form the alkanoyloxy group, and then obtaining the amino alcohol by reaction with thiourea, ethanol and glacial acetic acid. The amino alcohol can be reacted with sulphuric acid / formic acid or fuming sulphuric acid / formic acid to form the corresponding amino carboxylic acid. The amino, hydroxy, and carboxyl groups of the diamondoids can be converted into a plurality of other functional groups.

IPC Classes  ?

• C07C 41/09 - Preparation of ethers by dehydration of compounds containing hydroxy groups
• C07C 43/196 - Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring containing hydroxy or O-metal groups
• C07C 205/18 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings
• C07C 213/02 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
• C07C 215/42 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
• C07C 217/52 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
• C07C 227/02 - Formation of carboxyl groups in compounds containing amino groups, e.g. by oxidation of amino alcohols
• C07C 229/50 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
• C07C 231/06 - Preparation of carboxylic acid amides from nitriles by transformation of cyano groups into carboxamide groups
• C07C 233/23 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring

Abstract

The present invention relates to novel monoether derivatives of diols, the OH groups thereof being located in the 2 position of carbon atoms with π electron pairs, and a method for the production thereof. The monoether derivatives according to the invention are diols in which one of the two OH groups is etherized with a -CHR1 R2 protective group. R1 is an alkyl group, R2 stands for hydrogen or an alkyl group. The protective group contains at least one halogen atom, preferably fluorine. The mono-etherized diols make targeted production of derivatives of such diols whose OH groups are located in the 2 position of carbon atoms with π electron pairs possible. For example, the corresponding amino alcohols and amino carboxylic acids of benzyl, allyl and propargyl diols can be produced in this way in targeted fashion.

IPC Classes  ?

• C07C 43/178 - Unsaturated ethers containing hydroxy or O-metal groups
• C07C 41/09 - Preparation of ethers by dehydration of compounds containing hydroxy groups

Abstract

The invention relates to a method for producing a conductor/non-conductor transition on a substrate (1), the substrate (1) comprising a non-conductive metal oxide layer (2), wherein the non-conductive metal oxide layer (2) is made of metastable amorphous non-stoichiometric metal oxide (2) and is locally heated, wherein the locally heated region crystallizes into a stable non-conductive stoichiometric metal oxide (4), around which the metal concentration in the amorphous non-stoichiometric metal oxide increases, in particular forms a conductive region (5). The invention further relates to a storage medium for storing digital information, comprising a particularly round rotatable substrate (1) and a layer (2) disposed thereon for receiving digital information, wherein the layer (2) is configured by a non-conductive amorphous non-stoichiometric metal oxide, which can be transferred by means of local heating, particularly using a focused laser beam (3a, 3b) or an electron beam or a current pulse, at the location of the local heating into a region (4) made of crystallized, non-conductive stoichiometric metal oxide, which is surrounded by an increased metal concentration, particularly amorphous conductive non-stoichiometric metal oxide (5). The invention also relates to a method for producing an amorphous non-conductive non-stoichiometric metal oxide layer on a substrate (1), wherein the non-stoichiometric metal oxide layer (2) is removed from a target of the same metal oxide present in a stoichiometric form, and deposited onto the substrate.

IPC Classes  ?

• G11B 7/0045 - Recording
• G11B 7/242 - Record carriers characterised by the selection of the material of recording layers

Abstract

The present invention relates to a pharmaceutical, or to a process for the preparation of a pharmaceutical, for the treatment of fibrosing pulmonary diseases, in particular idiopathic pulmonal fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP). This involves using an agent which brings about a correction of the maladaptive ER stress response, which occurs in the alveolar type-II cells, or the blocking of the epithelial apoptosis.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to Cu-(ll)-oxygen adduct complexes, which are stable at room temperature, and to methods for the production thereof. These are compounds of the general formula [L-Cu-O-O-Cu-L](BAr4)2. To this end, BAr4 is a tetraarylborate anion, selected from tetraphenylborate and tetrakis(3,5-trifluoromethyl)phenylborate. L is a tripodal tetradentate ligand, wherein each of the four binding sites can be a nitrogen atom. Each of the three podal ligands, independently from each other, may comprise an aliphatic amine or a nitrogen-containing heteroaromat. Between the central nitrogen atom and the nitrogen atom of each of the podal ligands, a bridge comprising one to four carbon atoms is present. The Cu(ll)-oxygen adduct complexes according to the invention are produced in that first the ligand L is reacted into [Cu-L]X using a Cu-(I) salt. Then, the anion X of the Cu-(l) complex [Cu-L]X is replaced with tetraarylborate, and the compound [Cu-L]BAr4 that is obtained is finally subjected to an oxygen-containing atmosphere. In this process, [L-Cu-O-O-Cu- L](BAr4)2 forms. The Cu-(ll)-oxygen adduct complexes according to the invention can be used as oxidation catalysts, for example for the oxidation of benzene into phenol or methane, for the oxidation of hydrogen, aromatic and aliphatic, saturated and unsaturated hydrocarbons and also alcohols and amines. Furthermore, the verification of the Cu-(ll)-oxygen adduct complexes according to the invention can be used for the detection of oxygen.

IPC Classes  ?

• C07F 1/08 - Copper compounds
• C07F 5/02 - Boron compounds

Abstract

The present invention relates to an immortalized keratinocyte cell line from the gingiva and a cell culture system in which the cell line is used in order to test the effect of protective and/or modifying substances (such as anti-infectives, oral hygiene products) on the epithelial function of the gingiva/periodontium under in vitro conditions. The cells were infected with germs of the oral cavity and the effect of the potentially protective and/or modifying substances on the cells was measured, for example, by the change of the transepithelial electric resistance (TEER). The invention thereby replaces animal experiments and allows an analysis in high through-put.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The invention relates to the production, specific expression and permanent secretion of canine interleukins, especially interleukin-2 (clL-2) or interleukin-12 (clL-12) from transfected BHK-Tet-On cells and to the use of the lymphokine-activated killer cells produced thereby in the tumor therapy of dogs.

IPC Classes  ?

• C12P 21/00 - Preparation of peptides or proteins

Abstract

The invention relates to a method for specifically and sensitively detecting Mycobacterium avium ssp. paratuberculosis (MAP) in excrement, tissue, and organ samples by means of a real-time PCR process.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention describes a method for the verification of cholinergic neurons in tissue samples from a human or animal organism by detection of the SLC10A4 protein. SLC10A4 occurs exclusively in cholinergic neurons. In a preferred embodiment of the present invention, oligopeptides of the C-terminus of SLC10A4 are used to form polyclonal antibodies. For this purpose, the 422-437 amino acids of the SLC10A4 protein are coupled to the carboxy-terminal glutamic acid group on KLH. The protein that has been KLH-coupled in this manner is subsequently injected into a vertebrate, which subsequently forms polyclonal antibodies against SLC10A4. Polyclonal antibodies against SLC10A4 obtained in this manner are used according to the invention for detecting SLC10A4 in cholinergic neurons, for example, with the aid of the sandwich method in which, after incubation with the antibody according to the invention, an arbitrary second antibody is added by means of which the P4 protein is made optically visible. The visualization of SLC10A4 may occur, for example, by means of immunofluorescence or peroxidase staining.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention encompasses a cell line from the maternal portion of the placenta of pregnant bovine animals which undergoes permanent culture (BCEC Bovine Caruncular Epithelial Cells cell line) and is used in various in vitro assays inter alia for detecting the activity of substances on the epithelial barrier between maternal and fetal portion. The cell line is negative for the BVD virus and is also employed as in vitro assay for BVD infection studies.

IPC Classes  ?

• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention provides a method which is simple and easy to carry out for inducing insulin synthesis in isolated chorion cells which are obtained from the amnion. The cells are stimulated to insulin synthesis by the addition of L gastrin and GLP-1 or exendin-4, wherein a large quantity of insulin is released. The cells and the method for inducing insulin synthesis are thus suitable for the production of a means for treating diabetes mellitus.

IPC Classes  ?

• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues

Abstract

The invention relates to methods for producing particles comprising metals, semiconductors, metallic compounds or semiconductor compounds with diameters in the nanometer range. According to said methods, an electrochemically reducible precursor substance is dissolved in an ionic liquid, and is either reduced by free electrons in a plasma phase or is reacted with particles from the plasma phase. The particles obtained by the inventive method can be used, for example, as additives for polymers for coating medical instruments or as electrochemical catalysts. The particles can optionally be bound to or onto a substrate.

IPC Classes  ?

• B01J 19/08 - Processes employing the direct application of electric or wave energy, or particle radiationApparatus therefor
• B01J 19/12 - Processes employing the direct application of electric or wave energy, or particle radiationApparatus therefor employing electromagnetic waves
• B01J 13/00 - Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided forMaking microcapsules or microballoons

Abstract

The invention relates to 1-formamido-adamantane derivatives of formula (I), which carry the substituents R1, R2 or R3 in 3, 5 and/or 7 position, the substituents being defined as follows: hydrogen, a linear or branched alkyl, alkenyl or alkinyl group with up to 6 C atoms, an aliphatic or aromatic, cyclic or heterocyclic hydrocarbon group with up to 10 carbon atoms, and formamides of hydrocarbons from the group of diamondoids, for example diamantane, triamantane, tetramantane and pentamantane, however, with the exception of 1-formamido-3,5-dimethyladamantane. The invention also relates to a method for the direct formation of formamide or acetamide of adamantane, adamantane derivatives with the aforementioned definition of substituents or of a hydrocarbon from the group of diamondoids, characterized by reacting the adamantane, the adamantane derivative or the diamondoid with formamide, acetamide or acetonitrile in concentrated acids, while avoiding SO3 containing sulfuric acid or 100% azotic acid.

IPC Classes  ?

• C07C 233/03 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to hydrogen atoms
• C07C 231/08 - Preparation of carboxylic acid amides from amides by reaction at nitrogen atoms of carboxamide groups

Abstract

The invention relates to at least dinitroxylated diamantanes, and to methods by which means a high yield and selectivity of substituted diamantanes can be produced. According to the invention, dinitroxylated diamantanes can be reacted with nucleophiles to form the corresponding disubstituted diamantanes. Surprisingly, it was discovered that at least dinitroxylated or hydroxylated diamantanes are rearranged in the presence of a strong acid, creating at least 4,9-nitroxylated or hydroxylated diamantanes. On the basis of this, 4,9-substituted diamantanes can be produced in a targeted manner by reaction with other nucleophiles. The inventive methods for producing at least disubstituted diamantanes consist of the following steps: a) at least dinitroxylation, followed by substitution of all of the nitroxy groups with a nucleophile, or b) at least dinitroxylation, then rearrangement in the presence of a strong acid, all nitroxy groups being replaced by a nucleophile in the event of a successful rearrangement, or c) at least dinitroxylation, followed by a reaction with water (as nucleophile), and rearrangement of the at least dihydroxylated compound in the presence of a strong acid, all hydroxy groups being replaced by another nucleophile in the event of a successful rearrangement.

IPC Classes  ?

• C07C 13/615 - Adamantanes
• C07C 23/46 - Polycyclic halogenated hydrocarbons with condensed rings none of which is aromatic with more than 3 condensed rings

Abstract

The invention relates to a novel class of gas sensors for hydrogen or fluids (gases or liquids) containing hydrogen, such as hydrocarbons, hydrogen sulfides, or more complex gas mixtures or gas compositions containing hydrogen or hydrogen compounds. Both the reflection coefficient of the functional layer of the sensor and the change in the resistance of said layer are determined by means of one and the same sensor. The functional layer contains Mg and Ni or Mg and Al in an amorphous and/or microcrystalline and/or partly polycrystalline form.

IPC Classes  ?

• G01N 21/55 - Specular reflectivity
• G01N 27/12 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon absorption of a fluidInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon reaction with a fluid

Abstract

The invention relates to a rapid, safe method for predicting sepsis or a condition similar to sepsis, wherein clinical and genomic data is correlated in an optimal manner with expression profile special genes which is issued from the blood of patients.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids